Nionyx Bio's kidney gene therapy wins the 2026 BIO-Europe Spring Startup Spotlight

What It Covers

Magdalena Tyrpien, CEO and cofounder of Nionyx Bio, discusses the company's AAV-based gene therapy platform targeting rare kidney diseases, days after winning the BIO-Europe Spring 2026 Startup Spotlight in Lisbon. The six-month-old startup has raised $4M seed funding and targets an IND filing within 18 months.

Key Questions Answered

• •Human-first capsid development: Rather than developing AAV capsids in mouse models and hoping results translate, Nionyx Bio develops and validates capsids directly in human kidney and liver explants first, then works backward through animal models. This approach reduces clinical translation risk by confirming cell-specific targeting in the most predictive model available before entering IND-enabling studies.
• •Direct-to-kidney delivery to reduce systemic toxicity: Nionyx Bio administers AAV directly to the kidney rather than via systemic IV infusion, which historically routes the majority of vector to the liver and triggers ALT elevation and serious adverse events. This targeted delivery method enables lower doses while maintaining efficacy, addressing the liver toxicity issues that damaged gene therapy's reputation.
• •Trifecta platform for precision gene therapy: Nionyx Bio optimizes three independent variables simultaneously — capsid (cell-specific targeting), cassette (gene construct design), and delivery route — for each indication. For Alport syndrome, where the target gene exceeds single-AAV capacity, the team screened 11 dual-AAV constructs and identified one lead candidate before advancing to proof-of-concept mouse studies.
• •Capital efficiency as a competitive strategy: Nionyx Bio generated large animal dosing data, repeated kidney explant experiments, in vivo mouse data, and Alport cassette development on only $4M in seed funding within six months. Before a broader raise planned for the next quarter, founders should document each data milestone explicitly to demonstrate capital efficiency to Series A investors evaluating burn-to-progress ratios.
• •Competition wins as business development tools: Winning the BIO-Europe Spring Startup Spotlight generated immediate LinkedIn visibility, rekindled existing investor conversations, and opened new European investor relationships for a US-based company. Early-stage founders should target named pitch competitions with live jury feedback as structured business development events, not just validation exercises, particularly when expanding into new geographic investor markets.